Medicines update

Support for hepatitis treatment listing

Hepatitis Australia has welcomed recommendations to include three “ground-breaking curative antiviral therapies” on the PBS.

The announcement that the Pharmaceutical Benefits Advisory Committee (PBAC) recommends adding sofosbuvir (Sovaldi), ledipasvir/sofosbuvir (known as Harvoni overseas), and daclatasvir/ sofosbuvir (Daklinza/Sovaldi) to the PBS is a “watershed moment which will fundamentally change the way hepatitis C is treated in Australia”, the group claims.

Hepatitis Australia CEO, Helen Tyrrell